Skip to main content
Premium Trial:

Request an Annual Quote

New Numbers

AstraZeneca has reiterated that its SARS-CoV-2 vaccine is effective, saying that its latest analysis indicates it is 76 percent effective in preventing symptomatic COVID-19, the Associated Press reports.

Earlier this week, the company announced that a US-based trial of its SARS-CoV-2 vaccine developed with Oxford University was 79 percent effective in protecting against symptomatic COVID-19. But an independent data and safety panel soon informed US officials that it was concerned that the data AstraZeneca released was outdated and possibly misleading.

In its newly released data, AstraZeneca presents adjusted, though similar numbers, as the Verge notes. Business Insider adds that the new data indicate the vaccine is between 68 percent and 82 percent effective, and experts tell the AP that the new numbers are "reassuring."

"The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over," Mene Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca, says in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.